SOPHROSYNE CAPITAL LLC
Q1 2014 13F-HR Holdings
Net value change ($000)
+7
(0.0%)
New positions
29
Sold out positions
16
Turnover %
29.5%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| SYNGENTA AG | 5,940 | 5500.0% |
| Benefytt Technologies, Inc. | 4,651 | NEW |
| MEETME INC | 2,244 | 55.5% |
| SHORETEL INC | 2,095 | NEW |
| SANW | 1,848 | 374.8% |
| NUVERRA ENVIRONMENTAL SOLUTI | 1,571 | NEW |
| DURATA THERAPEUTICS INC | 1,422 | NEW |
| BIOTELEMETRY, INC. | 1,302 | 13.3% |
| UI | 930 | 47.7% |
| NKTR | 728 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| CALX | -6,163 | -100.0% |
| DURECT CORP | -3,137 | -100.0% |
| LSAK | -2,368 | -38.4% |
| ARAY | -2,128 | -46.2% |
| Zeltiq Aesthetics Inc | -2,013 | -20.9% |
| VSTM | -1,267 | -100.0% |
| AXGN | -1,154 | -40.7% |
| PAIN THERAPEUTICS INC | -979 | -15.9% |
| NEOSTEM INC | -963 | -100.0% |
| CYAN INC | -912 | -48.6% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|